Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York
Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

October 17, 2019 Capital Markets and Public M&A

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge advises Latour on the sale of shares in ASSA ABLOY and Securitas, amounting to SEK 2.5 billion in each company

 Vinge has advised Investmentaktiebolaget Latour (publ) in connection with the sale of parts of its shareholdings in ASSA ABLOY and Securitas for a total value of SEK 5 billion.
May 27, 2026

Vinge advises Hybridge Group on the acquisition of NESC

 Hybridge Group and the consultancy firm NESC are merging. Through the merger, Hybridge Group is strengthening its offering in the field of prefabricated structural solutions.
May 27, 2026

Vinge advises Natur & Kultur in connection with the acquisition of Majema

 Natur & Kultur has acquired 80 per cent of the shares in the educational publisher Majema. The acquisition is a strategic, long-term step in Natur & Kultur’s investment in educational materials.
May 27, 2026